Telephone
61.8.9360.2888
Address
Building 191 90 South Street Murdoch University Murdoch, Western Australia (WA) 6150
Description
Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. Its products include CelGro, which is a naturally derived collagen medical device for soft tissue repair; and Antilogous Tenocyte Implantation for chronic treatment resistant tendon injuries. The company was founded by Paul Frederick Anderson and Ming Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.36 - 1.79
Trade Value (12mth)
AU$330,873.00
1 week
-7.81%
1 month
-1.59%
YTD
-14.48%
1 year
210%
All time high
1.79
EPS 3 yr Growth
-26.40%
EBITDA Margin
-210.00%
Operating Cashflow
-$7m
Free Cash Flow Return
-112.10%
ROIC
-123.80%
Interest Coverage
N/A
Quick Ratio
4.10
Shares on Issue (Fully Dilluted)
216m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.05
Date | Announcements |
---|---|
10 July 25 |
Orthocell Announces First US Remplir Sales Revenue
×
Orthocell Announces First US Remplir Sales Revenue |
10 July 25 |
Application for quotation of securities - OCC
×
Application for quotation of securities - OCC |
10 July 25 |
Cleansing Notice
×
Cleansing Notice |
09 July 25 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
02 July 25 |
Orthocell Bolsters Leadership with Key Hires
×
Orthocell Bolsters Leadership with Key Hires |
02 July 25 |
Remplir US Rollout & 1st Surgery Investor Update
×
Remplir US Rollout & 1st Surgery Investor Update |
01 July 25 |
Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ
×
Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ |
27 June 25 |
First Surgical Use of Remplir in US$1.6 Billion US Market
×
First Surgical Use of Remplir in US$1.6 Billion US Market |
27 June 25 |
Investor Webinar
×
Investor Webinar |
19 June 25 |
Compelling Data Highlights Remplir Competitive Advantage
×
Compelling Data Highlights Remplir Competitive Advantage |
10 June 25 |
Application for quotation of securities - OCC
×
Application for quotation of securities - OCC |
10 June 25 |
Cleansing Notice
×
Cleansing Notice |
12 May 25 |
Remplir Approved to Commence Sales in the Hong Kong Market
×
Remplir Approved to Commence Sales in the Hong Kong Market |
09 May 25 |
12 Distributors Signed for Remplir Covering 21 States in US
×
12 Distributors Signed for Remplir Covering 21 States in US |
30 April 25 |
Remplir Approved to Commence Sales in US$75m Canadian Market
×
Remplir Approved to Commence Sales in US$75m Canadian Market |
29 April 25 |
Pause in Trading
×
Pause in Trading |
29 April 25 |
Trading Halt
×
Trading Halt |
29 April 25 |
Replacement Trading Halt
×
Replacement Trading Halt |
28 April 25 |
Remplir Approved to Commence Sales in US$84M Thai Market
×
Remplir Approved to Commence Sales in US$84M Thai Market |
23 April 25 |
First US Distributors Signed for Remplirs US$1.6B market
×
First US Distributors Signed for Remplirs US$1.6B market |
14 April 25 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
10 April 25 |
Remplir Regulatory Application Submitted for Hong Kong
×
Remplir Regulatory Application Submitted for Hong Kong |
09 April 25 |
Regulatory Approval for Striate in US$65M Brazilian Market
×
Regulatory Approval for Striate in US$65M Brazilian Market |
04 April 25 |
Remplir Cleared to Commence Sales in US$1.6B US Market
×
Remplir Cleared to Commence Sales in US$1.6B US Market |
04 April 25 |
Investor Presentation - US FDA 510(k) Clearance for Remplir
×
Investor Presentation - US FDA 510(k) Clearance for Remplir |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.